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Abstract 
Background: Achromatopsia (ACHM) is a severe congenital autosomal recessive retinal disorder caused by loss of 
cone photoreceptors. Here, we aimed to determine the underlying genetic lesions and phenotypic correlations in 
two Chinese families with ACHM.
Methods: Medical history and clinical evaluation were obtained from both families. Targeted exome sequencing 
(TES) was performed on 201 disease‑causing genes of inherited retinal dystrophies to screen for ACHM causative 
mutations in the two probands.
Results: The compound heterozygous mutations in CNGA3 (c.1074G > A, p.W358X; c.1706G > A, p.R569H) were 
identified in the first proband, and a novel homozygous mutation (c.968C > A, p.A323D) was detected in the other 
pedigree. The proposed topological model of the CNGA3 polypeptide suggested that the missense mutations primar‑
ily affected the transmembrane helix 5 and the cGMP‑binding domain, respectively. Crystal structure modeling of 
the cyclic nucleotide‑gated cation channel α‑3 (CNGA3) protein encoded by the CNGA3 gene revealed an abnormal 
combined structure generated by R569H.
Conclusions: We firstly used the TES approach to identify genetic alterations in patients with ACHM. We uncovered 
three mutations in CNGA3, including one novel mutation. Our results not only expand the genotypic spectrum for 
CNGA3 mutations, but also demonstrate that the TES approach is a valuable tool for molecular diagnosis.
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Background
Achromatopsia (ACHM) is an early-onset and mostly 
stationary retinal dystrophy characterized by amblyopia 
(severely reduced visual acuity), pendular nystagmus, 
photophobia, and reduced or complete loss of color dis-
crimination [1]. Currently, the diagnosis of ACHM is 
based on medical history, typical clinical manifestations, 
color discrimination problems in color vision testing, 
absent or reduced photopic (cone) responses and normal 
scotopic (rod) responses in electroretinograms (ERGs), 
and the presence of a normal fundus or only minor 
changes upon fundus photography [2].
To date, five causative genes (CNGA3, CNGB3, GNAT2, 
PDE6C and PDE6H) have been identified in ACHM 
patients [1, 3–6]. These genes encode crucial compo-
nents of the cone phototransduction cascade. Mutations 
in CNGA3 and CNGB3, which encode the α-subunit and 
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β-subunit of the CNG, account for 25 % and 40–50 % of 
affected individuals in multiple ethnic groups, respec-
tively [3, 7]. Mutations in CNGA3 are considered the 
most common cause of ACHM and cone-rod dystrophies 
(CORDs) in Chinese, in which only cone photoreceptors 
are usually affected, although CNGA3 mutations have 
been reported in a patient with CORDs and Leber con-
genital amaurosis (LCA) [8, 9]. However, approximately 
20–30  % of ACHM cases appear to lack pathogenic 
mutations, which is likely due to the limitations in the 
number of screened regions [1, 3–5, 10].
Traditional techniques using Sanger sequencing for 
molecular diagnosis have several limitations, including 
being time-intensive and inconvenient for large scale 
analysis. Next-generation sequencing (NGS) has been 
shown to identify variants rapidly and systematically on 
an extremely large scale, which has greatly accelerated 
the development of gene discovery and molecular diag-
nosis [11]. NGS is increasingly being used for discovery 
of causative genes of Mendelian diseases and for genetic 
diagnosis [12, 13]. Targeted exome sequencing (TES) is 
an efficient method of NGS based on custom designed 
capture panels. TES can be used to identify disease-caus-
ing genes and to screen for mutations in hundreds of loci 
in genetically heterogeneous diseases. TES is less costly 
than whole genome sequencing (WGS) for mapped chro-
mosomal regions, as well as for whole exome sequenc-
ing (WES). Thus, TES has several advantages compared 
to other approaches for reducing costs while enriching 
for discovery of highly penetrant variants [14], and for 
identifying pathogenic mutations with respect to both 
efficiency and accuracy. To date, some studies performed 
WES and detected causative mutations of ACHM [15, 
16], but these lacked the TES approach to aid in molecu-
lar diagnosis of ACHM. Considering the enormous geno-
typic and phenotypic heterogeneity of inherited retinal 
dystrophies, there remains great potential to discover 
novel mutations or genes. In our study, we performed 
TES to screen 201 disease-causing genes of inherited ret-
inal dystrophies in two families with ACHM, and discov-
ered novel disease causative mutations, which broaden 
the spectrum of ACHM in Chinese.
Methods
Participants and clinical evaluations
The study protocol was designed in adherence to the ten-
ets of the Declaration of Helsinki, and was approved by 
the Ethics Committee of the Eye Hospital of Wenzhou 
Medical University. Nine participants from two unrelated 
families, including two patients and seven unaffected 
family members (Fig.  1a) were recruited to this study. 
Informed consent was obtained from all participants 
or their statutory guardian prior to the study. Patients’ 
initial symptoms and complaints included poor visual 
acuity and pendular nystagmus at an early age. Patients 
received a clinical diagnosis based on medical history, 
routine ophthalmological examination, and specialized 
visual function testing, including color vision testing, 
fundus photography and ERGs. A detailed family history 
was obtained from the patients and/or their relatives, and 
peripheral blood samples were collected.
Targeted exome sequencing
We extracted a minimum of 3 μg of genomic DNA from 
each blood sample and fragmented it in order to con-
struct the DNA library. One patient from each family was 
selected for TES. Biotinylated single-strand DNA capture 
probes were hybridized in solution with the target library. 
Streptavidin-coated magnetic beads were used to wash, 
elute, and amplify the DNA, which was then subjected 
to NGS using an Illumina Solexa HiSeq 2000 sequencer. 
A previously described targeted capture panel including 
201 disease-causing genes (Additional file 1: Table S1) of 
inherited retinal dystrophies was applied for mutation 
screening in both pairs of patients [17].
In‑depth bioinformatics analyses and Sanger sequencing
The following databases were used for annotation of all 
identified variants: HapMap Project (http://hapmap.ncbi.
nlm.nih.gov/), dbSNP137 (http://hgdownload.cse.ucsc.
edu/goldenPath/hg19/database), 1000 Genome Project 
(ftp://1000genomes.ebi.ac.uk/vol1/ftp), Exome Variant 
Server (http://evs.gs.washington.edu/EVS/) and ExAC 
(http://exac.broadinstitute.org/). For variants that passed 
the initial filtration, we performed Sanger sequencing 
(Fig. 1b) and segregation analysis of the candidate mutant 
alleles in each patient’s family. To evaluate the different 
identified sequence variations, we analyzed 200 healthy 
control DNA samples.
In silico analyses
The pathogenicity of the variant was assessed using in 
silico predicting online available programs, including 
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), 
SIFT (http://sift.jcvi.org/www/SIFT_enst_submit.html), 
and MutationTaster (http://www.mutationtaster.org/) for 
missense variants. Together, these assessments provided 
information on the pathogenicity of the variant. The top-
ological model of the CNGA3 polypeptide was predicted 
using SMART (http://smart.embl-heidelberg.de/). The 
crystal structures of the wild-type and mutant proteins 
were predicted using Phyre2 (http://www.sbg.bio.ic.ac.
uk/phyre2/html/page.cgi?id=index) [18] and visualized 
with PyMol software (Version 1.5). The model structure 
of the human cone CNG comprised of two CNGA3 and 
two CNGB3 subunits was previously described [19].
Page 3 of 8Li et al. J Transl Med  (2015) 13:334 
Results
Clinical findings
One patient from each family was clinically diagnosed 
with ACHM, and their detailed clinical features and 
mutations were summarized in Table 1. F1-II:2 reported 
to have evident nystagmus within the first few months 
after birth. Coincidentally, F2-IV:1 is a 29  year-old man 
with evident poor vision accompanied by nystagmus. The 
fundus presented with temporal disc pallor in F2-IV:1, 
and F1-II:2 only showed poor foveal reflex. There was 
no family history of ophthalmic disease, but the patient 
F2-IV:1 was from a consanguineous family. Both patients 
had normal anterior segments, ocular media, severe 
photophobia, and were unable to perform color-dis-
crimination tasks. ERGs revealed severely reduced cone 
responses and normal rod response. Since ERGs were 
Fig. 1 Pedigrees and identified mutations. a Pedigrees of two families were demonstrated with CNGA3 genotypes was annotated to included fam‑
ily members. Probands are indicated by arrows. Circles females; squares males; filled symbols affected patients; empty symbols unaffected controls. b 
DNA sequencing profiles of the identified mutations (upper) and their wild‑type form (under)
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incomplete in young children, we only obtained results 
from F2-IV:1. All clinical manifestations were typical of 
complete ACHM.
Mutations identified by TES
We used a panel covering 201 disease-causing genes of 
inherited retinal dystrophies to screen for ACHM muta-
tions. Our TES reached an average mean depth of 168X 
with greater than 97.8 % coverage of the targeted regions. 
After alignment and bioinformatics analyses, single 
nucleotide variants (SNVs) and insertions/deletions 
(Indels) were annotated to the exome databases, of which 
those with MAF >0.005 or found homozygous >1 subject 
were filtered. The missense variants were discarded with 
tolerant prediction using in silico tools. Candidate vari-
ants were then confirmed in the family members. In total, 
compound heterozygous mutations and one homozygous 
mutation in the CNGA3 gene were identified in the two 
families (Fig. 1a, b). In family 1, the proband F1-II:2 har-
bored two different heterozygous mutations in CNGA3 
(c.1074G > A, p.W358X; c.1706G > A, p.R569H), which 
were demonstrated to originate from the paternal and 
maternal allele, respectively. His healthy sister carried a 
heterozygous mutation (c.1074G  >  A, p.W358X). Both 
of these mutations were identified in previous studies 
[7, 8, 20]. In family 2, the proband F2-IV:1 harbored one 
homozygous mutation in CNGA3 (c.968C > A, p.A323D), 
as a result of being consanguineous to the F2 family. His 
healthy sister (IV:3) carried a heterozygous mutation and 
brother (IV:4) has normal genotype. To the best of our 
knowledge, this is the first report of the A323D mutation. 
These two missense mutations were predicted to be dele-
terious based on three types of online predictive software 
(Table  2). We aimed to detect whether any of the three 
potential mutations existed in normal populations, so 
direct Sanger sequencing of the three points were applied 
in 200 healthy controls. Finally, all the three potential 
mutations were absent in the 200 controls.
Structural modeling
The first G-A substitution (W358X) in exon 7 of the 
CNGA3 gene is predicted to generate a premature termi-
nation codon (PTC) at residue 358 of the CNGA3 pro-
tein (Fig. 2a). The second mutation (R569H) is a missense 
mutation that changes Arginine to Histidine at residue 
569. The A323D mutation was a novel missense substi-
tution from Alanine to the Aspartic acid at residue 323. 
The proposed topological model of the CNGA3 polypep-
tide included the six transmembrane helices (S1–S6), the 
ion pore, and the cGMP-binding domain [7, 21]. Both 
the R569H and A323D missense mutations affected 
evolutionarily highly conserved amino acid residues in 
CNGA3; R569H is located in the cGMP-binding domain 
while A323D mostly affects transmembrane helix S5 
(Fig.  2a, b). Structural modeling revealed the genera-
tion of a novel bond between the mutated Histidine at 
residue 569 and Tyrosine at residue 508 (Fig. 3a, b). The 
other homozygous mutation (A323D) changes Alanine 
to Aspartic acid (Fig. 3c, d). The model structure of the 
human cone CNG, which is comprised of two CNGA3 
(α) and two CNGB3 (β) subunits (Fig.  3e, f ), revealed 
that both mutations affect highly conserved residues. 
Table 1 Clinical features of the ACHM patients in this study
M male, NYS nystagmus, PP photophobia, BCVA best corrected visual acuity, OD right eye, OS left eye, PV poor vision, PFR poor foveal reflex, TDP temporal disc pallor, 
ERGs electroretinograms, NA not available






Exam Onset NYS PP PV OD OS OD OS Rods Cones
Family1‑II:2 CNGA3 c.1074G > A; c.1706G > A M 6 years 2 months + + + 0.05 0.05 PFR PFR NA NA
Family2‑IV:1 CNGA3 c.968C > A; c.968C > A M 29 years <7 years + + + 0.12 0.12 TDP TDP Normal Severely reduced
Table 2 CNGA3 mutations identified in the study
Het heterozygous, Hom homozygous, D deleterious, PD probably damaging, DC disease-causing
Family ID Exon Variation PolyPhen2 SIFT Mutation taster DbSNP References
Nucleotide Protein Status Type
Family1 7 c.1074G > A p.W358X Het Nonsense – – – Novel [8]
Family1 7 c.1706G > A p.R569H Het Missense PD (0.991) D (0.00) DC (0.999) Novel [7, 20]
Family2 7 c.968C > A p.A323D Hom Missense PD (0.960) D (0.02) DC (0.999) Novel This study
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Although there was no apparent change in the œ-subu-
nits. These mutations significantly affect the combination 
between α-subunit and ß-subunit. Structural modeling 
was constructed on the basis of the crystal structure of 
template c4chwB [18], which demonstrated sequence 
coverage of 49 % with the protein cyclic nucleotide-gated 
ion channel α-subunit.
Discussion
Achromatopsia (ACHM) is a severe congenital auto-
somal recessive retinal disorder caused by loss of cone 
photoreceptors. Mutations in the CNGA3 gene are rec-
ognized as the most common causes of ACHM and 
cone-rod dystrophies in the Chinese population [8]. In 
our study, we report three distinct disease-causative 
CNGA3 mutations, including one novel variant and two 
known mutations, in two Chinese families with ACHM. 
Two heterozygous mutations in F1 have been previously 
reported, however this type of compound CNGA3 muta-
tion has not been described to date. Furthermore, we 
reveal for the first time a novel homozygous missense 
(A323D) in CNGA3 that leads to ACHM.
The CNGA3 gene, located on chromosome 2q11, 
contains 7 exons. CNGA3 and CNGB3 encode the 
α- and β-subunits that composed to the cone CNG. 
Heterologous expression studies have shown that the 
α-subunits are responsible for the ion-conducting 
activity of the channel, whereas the β-subunits func-
tion as modulators [21]. A study using a homologous 
Cnga3 knockout-mouse model demonstrated complete 
absence of physiologically measurable cone function, 
a decrease in the number of cones in the retina, and 
Fig. 2 Mutations identified in two families. a Multiple sequence alignment of CNGA3 polypeptides of different species showing the conserved 
amino acid residues (Arginine 569 and Alanine 323). b Exons of the CNGA3 gene (upper) and location of the mutations with respect to the topologi‑
cal model of the CNGA3 polypeptide
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morphological abnormalities of the remaining cones 
[22]. The compound heterozygous mutations, W358X 
and R569H, are unable to retain crucial functional 
activity. The R569H heterozygous and A323D homozy-
gous mutations are mainly confined to the functionally 
and structurally important central parts of the CNGA3 
polypeptide, affecting the S5 and the cGMP-binding 
domains, respectively. Crystal structure modeling sug-
gests that R569H impacts on the generation of bonds, 
while A323D is not predicted to significantly influence 
the spatial conformation of the protein. However, the 
addition of hydrogen could potentially affect the asso-
ciation with the β-subunit, as both mutants localize to 
highly conversed residues.
Fig. 3 Predicted crystal structures of CNGA3 protein. Predicted crystal structures of wild‑type (a, c) and mutant (b, d) CNGA3 protein. Side view 
(e) and extracellular view (f) of the transmembrane domain of the cone CNG model structure. The proposed locations of the two CNGA3 and two 
CNGB3 subunits are marked. Magenta coloring indicates residue 569, while pink represents residue 323
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Patients in both families showed typical clinical mani-
festations of ACHM. The importance of CNGA3 muta-
tions is underscored by the finding that these mutations 
not only cause complete ACHM, but also incomplete 
ACHM [7]. With respect to incomplete ACHM, com-
bined clinical diagnosis with diagnostic panels used for 
genetic testing can improve the sensitivity of diagnosis. 
Ophthalmological evaluation, including color vision test-
ing, fundus photography and ERGs. Color vision testing 
was unable to be performed in cases of severe photo-
phobia and poor visual acuity. Fundus photography and 
ERGs are time-consuming, and can be stressful for the 
patient. Moreover, clinical investigations are sometimes 
incomplete in children or might require general anaes-
thesia. Moreover, genetic testing in the patients allowed a 
focused analysis opportunity for genetic risk assessment 
and genetic counselling [2].
To date, a small number of studies have focused on gene 
therapy in patients carrying mutations in the CNGA3 
gene [23, 24]. Using the novel TES approach described in 
our study, one can confirm the clinical diagnosis and rap-
idly identify the mutations, which greatly enables thera-
peutic intervention and personalized medicine.
Conclusions
In summary, we used the paneled exome sequenc-
ing methodology for molecular diagnosis of inherited 
ACHM, and identified three mutations in two patients, 
including two compound mutations and one novel 
homozygous mutation. TES can be used for both inves-
tigative and diagnostic purposes as this technique can 
identify the disease causing mutations. Genetic testing is 
a useful tool to complement diagnostic procedures, and 
TES can be of particular benefit to children with early-
onset ACHM.
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